Evidence map›Paper›PMID 34606128›Full record

ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2022

SARS-CoV-2 serology in patients on biological therapy or apremilast for psoriasis: a study of 93 patients in the Italian red zone.

S M A Ahmed, M Volontè, E Isoletta, C Vassallo, C F Tomasini, D Lilleri, P Zelini, V Musella, C Klersy, V Brazzelli

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

S M A AhmedInstitute of Dermatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy.
M VolontèInstitute of Dermatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy.
E IsolettaInstitute of Dermatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy.
C VassalloInstitute of Dermatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy.
C F TomasiniInstitute of Dermatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy.
D LilleriMolecular Virology Unit, Department of Microbiology and Virology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
P ZeliniDepartment of Obstetrics and Gynecology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy.
V MusellaUnit of Clinical Epidemiology and Biometrics, Scientific Direction, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
C KlersyUnit of Clinical Epidemiology and Biometrics, Scientific Direction, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
V BrazzelliInstitute of Dermatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy.ORCID https://orcid.org/0000-0001-5898-6448

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19PsoriasisAnti-Inflammatory Agents, Non-SteroidalBiological TherapyHumansSARS-CoV-2Severity of Illness IndexThalidomideAnti-Inflammatory Agents, Non-SteroidalapremilastThalidomide

Identifiers

PMID34606128
PMCPMC8656363

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.